Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
US Department of Justice
Merck
QuintilesIMS
Farmers Insurance
Fish and Richardson
Healthtrust
Baxter

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203137

« Back to Dashboard

NDA 203137 describes VIZAMYL, which is a drug marketed by Ge Healthcare and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the VIZAMYL profile page.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.
Summary for 203137
Tradename:VIZAMYL
Applicant:Ge Healthcare
Ingredient:flutemetamol f-18
Patents:5
Pharmacology for NDA: 203137
Mechanism of ActionRadiopharmaceutical Activity
Suppliers and Packaging for NDA: 203137
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137 NDA Medi-Physics Inc. 17156-067 N 17156-067-30
VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137 NDA Medi-Physics Inc. 17156-067 N 17156-067-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength40.5mCi/10ML (4.05mCi/ML)
Approval Date:Oct 25, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 25, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Sep 3, 2025Product Flag?YSubstance Flag?YDelist Request?
Patented Use:DIAGNOSTIC RADIOIMAGING
Patent:➤ Try a Free TrialPatent Expiration:Jan 24, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:DIAGNOSTIC RADIOIMAGING

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Citi
US Department of Justice
Merck
QuintilesIMS
Covington
AstraZeneca
Moodys
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.